Immunogenicity of one dose and two doses of adjuvanted influenza vaccine in lung transplant candidates
Polishchuk V. Kostinov M. Ryzhov A. Dagil Y. Khrapunova I. Zhestkov A. Tarabrin E. Karchevskaya N. Vlasenko A. Kostinova A. Poddubikov A. Solovieva I. Khamidulina A. Prutskova E. Mekhantseva I.
September 2025Public Library of Science
PLOS ONE
2025#20Issue 9 September
Influenza is especially dangerous for high-risk patients, for whom various vaccination strategies are used to prevent this disease. This study assessed the safety and immunological effectiveness of an inactivated trivalent polymer-subunit influenza vaccine Grippol® Plus administered according to two regimens in a group of 41 patients with severe progressive bronchopulmonary disorders. It also investigated the duration of vaccine-induced antibody response in this patient population. Group 1 of the study subjects (n = 21) received one dose of Grippol® Plus, and Group 2 (n = 20) received two doses of Grippol® Plus one month apart in the same influenza season. To measure antibody levels, paired sera were tested in hemagglutination inhibition assay pre-vaccination and at months 1 and 12 post-vaccination. Vaccine immunogenicity was assessed by the Committee for Medicinal Products for Human Use (CHMP) criteria. All patients were symptom-free in the post-vaccination period. The one-dose regimen met all CHMP criteria against strains A/California/7/2009(H1N1)pdm09-like and A/Texas/50/2012(H3N2) and the criteria for seroprotection and seroconversion against the B/Massachusetts/2/2012 strain. This regimen was associated with a significant increase in Ab titers against all the three influenza viral strains. In the two-dose group, no statistically significant differences were observed in IgG Ab levels, seroprotection rate, seroconversion rate or seroconversion factor at month 1 after the first and second vaccine doses. At month 12 post-vaccination, Ab levels returned to baseline, regardless the vaccination regimen. In lung transplant candidates, one-dose vaccination with an inactivated trivalent polymer-subunit influenza vaccine was effective in generating protective antibody levels for the current influenza season.
Text of the article Перейти на текст статьи
Laboratory for Vaccination and Immunotherapy of Allergic Diseases, I. I. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russian Federation
Department of Epidemiology and Modern Vaccination Technology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
Laboratory of Clinical Immunology, National Research Center, Institute of Immunology, Federal Medical and Biological Agency of Russia, Moscow, Russian Federation
Department of Clinical Medicine, Medical University “Reaviz”, Samara, Russian Federation
Department of Hospital Surgery, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
Department of Thoracic and Abdominal Surgery, N.V. Sklifosovsky Research Institute for Emergency Medicine, Moscow, Russian Federation
Center for Evidence-Based Medicine and Biostatistics, Samara State Medical University, Samara, Russian Federation
N.V. Sklifosovsky Institute of Clinical Medicine, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
Department of Pediatrics, Ulyanovsk State University, Ulyanovsk, Russian Federation
Department of Internal Medicine, Karaganda Medical University, Karaganda, Kazakhstan
Laboratory for Vaccination and Immunotherapy of Allergic Diseases
Department of Epidemiology and Modern Vaccination Technology
Laboratory of Clinical Immunology
Department of Clinical Medicine
Department of Hospital Surgery
Department of Thoracic and Abdominal Surgery
Center for Evidence-Based Medicine and Biostatistics
N.V. Sklifosovsky Institute of Clinical Medicine
Department of Pediatrics
Department of Internal Medicine
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026